Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontline Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer
NCT02844582Phase 2Terminated
- Sponsor
- University of California, Davis
- Start
- Dec 2017
- Primary completion
- Jun 2019
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of California, Davis. Started Dec 2017; status: terminated.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02844582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844582.